Your rescue dog gets terminal cancer. Traditional treatments fail. So you fire up ChatGPT and design a personalized mRNA vaccine that shrinks the tumor by half. Paul Conyngham’s story sounds like science fiction, but it’s the most concrete example yet of AI tools democratizing cutting-edge medicine.
Conyngham, a Sydney machine learning consultant with 17 years in AI but zero biology training, pulled off what pharmaceutical companies spend millions attempting. When his Staffy-Shar Pei mix Rosie developed aggressive mast cell cancer in 2024, conventional chemotherapy and surgery couldn’t stop the tumors. That’s when consumer AI became life-saving medicine.
From Chatbot to Genomics Lab
ChatGPT suggested immunotherapy; AlphaFold identified the molecular targets.
The methodology reads like a tech startup pivot story:
- ChatGPT recommended immunotherapy as a potential pathway
- Conyngham contacted the University of New South Wales genomics center, which sequenced Rosie’s DNA for $3,000—comparing healthy cells to tumor cells like examining “a brand-new car engine with one that has 186,000 miles” to identify exact damage points
- Google DeepMind’s AlphaFold protein analysis tool matched the mutations to potential treatments
When a pharmaceutical company’s immunotherapy drug proved unavailable for compassionate use, discussions shifted to mRNA vaccine technology. The same platform that powered COVID-19 vaccines could theoretically train Rosie’s immune system to attack her specific cancer mutations.
The Results That Matter
Three months of ethics paperwork led to a tennis ball-sized tumor shrinking by half.
Securing approval required university validation—Conyngham spent three months compiling a 100-page ethics application, working two hours nightly. UNSW RNA Institute director Pall Thordarson transformed Conyngham’s genomic data into a functional mRNA vaccine formula.
Rosie received her first injection in December 2024, followed by boosters. The outcome exceeded expectations: her largest tumor halved in size. “I’m under no illusion that this is a cure, but I do believe this treatment has bought Rosie significantly more time and quality of life,” Conyngham said. He’s currently developing a second vaccine targeting remaining tumors.
Beyond One Dog’s Story
This represents the first AI-designed personalized cancer vaccine for any animal.
Thordarson emphasized this breakthrough demonstrates how mRNA technology can enable rapid, personalized medicine with potential human applications. The timing aligns with parallel AI-cancer advances: German researchers recently developed CHIEF, a ChatGPT-like model achieving 94% accuracy detecting cancer across 11 types.
Yet Conyngham’s approach required crucial university partnerships and formal ethics approval—distinguishing legitimate innovation from dangerous DIY experimentation. His case suggests AI tools can democratize access to sophisticated biomedical research, but only when proper oversight ensures safety and scientific rigor guide the process.
